Meta-analysis: PD-1/PD-L1 inhibitors show 45% ORR, 16.27-month median OS in recurrent/metastatic NPC
For advanced nasopharyngeal cancer, can immune therapy help? New analysis shows what patients might expect
A meta-analysis of 9 studies (883 patients) found PD-1/PD-L1 inhibitors for recurrent/metastatic nasopharyngeal carcinoma yielded a median O…
For advanced nasopharyngeal cancer, immune therapy helps 43% stay cancer-free for a year while 80% survive, though side effects affect 90% o…
Photobiomodulation reduces severe oral mucositis (RR 0.46) and pain (RR 0.35) in head and neck cancer patients
Can light therapy ease the brutal mouth sores and pain of head and neck cancer treatment? A review of 30 studies suggests it can
A meta-analysis of 30 RCTs (n=1748) found photobiomodulation significantly reduced the risk of severe oral mucositis (RR 0.46, 95% CI: 0.29-…
A review of 30 studies shows light therapy significantly reduces severe mouth sores and pain for head and neck cancer patients while improvi…
Asciminib superior to IS-TKIs in newly diagnosed CML-CP: MMR 74.1% vs 52.0% at 96 weeks
Could a new leukemia drug work better and cause fewer side effects than current treatments?
In the ASC4FIRST trial, asciminib demonstrated superior efficacy vs investigator-selected TKIs (IS-TKIs) in newly diagnosed CML-CP.
A new leukemia drug helped more patients reach deep disease control with fewer side effects than current standard treatments after two years…
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
Can a new drug combination help people with aggressive multiple myeloma? Early results show promise
In a phase 2 trial of 29 patients with newly diagnosed multiple myeloma and extramedullary disease (EMD), selinexor combined with VRD (SVRD)…
A new four-drug combination helped nearly 90% of patients with aggressive multiple myeloma shrink or eliminate cancer outside the bone marro…
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.
FMT + Nivolumab Shows 20% ORR in 10 ICI-Refractory GI Cancer Patients
Could a gut bacteria transplant help when immunotherapy stops working for stomach cancer?
A phase I study in 10 patients with anti-PD-(L)1-refractory GI cancers found the combination of fecal microbiota transplantation (FMT) and n…
When stomach cancer resists standard immunotherapy, a gut bacteria transplant combined with treatment helped tumors shrink in two patients a…
Edoxaban 12 months superior to 3 months for VTE prevention in cancer DVT, regardless of anemia status
For cancer patients with a leg blood clot and anemia, does longer treatment work better?
In this prespecified subgroup analysis of the ONCO DVT study, 12 months of edoxaban was superior to 3 months for preventing symptomatic recu…
Cancer patients with leg clots and anemia get better protection against new clots with 12 months of edoxaban compared to just 3 months, with…
Induction Nivolumab Before CRT Misses Feasibility Threshold in High-Risk HPV+ OPC
Can a new approach reduce relapse in high-risk throat cancer? Early results show promise but raise safety concerns
In a phase II RCT of high-risk HPV-positive oropharyngeal cancer patients, induction nivolumab before chemoradiation did not meet the predef…
Adding immunotherapy before standard treatment reduced cancer relapse in high-risk throat cancer patients, though severe side effects preven…
Camizestrant 75 mg achieves maximal ER reduction in 5-7 days, well-tolerated in SERENA-3 WOO trial
Can a new breast cancer drug work in just days? Study shows it quickly reduces tumor fuel and slows growth
In the presurgical SERENA-3 trial, camizestrant reduced ER expression by ~65% across all doses (75, 150, 300 mg) by 5-7 days in postmenopaus…
A new breast cancer drug cuts tumor fuel by 65% in just five to seven days and slows growth with minimal side effects at the lowest dose.
PD-1 inhibitors + chemo improve OS, PFS, ORR in first-line advanced ESCC; benefit limited in PD-L1 CPS <1
Who benefits most from new esophageal cancer treatment? Most patients do, except one group
A meta-analysis of 8 RCTs (n=4702) found first-line PD-1 inhibitors plus chemotherapy significantly improved OS (HR=0.68, 95% CI: 0.63-0.74;…
For most advanced esophageal cancer patients, adding immunotherapy to chemotherapy extends life and shrinks tumors, but those with low PD-L1…
Home treatment for low-risk cancer-associated PE shows 4.6% major bleeding rate in ONCO PE companion report
Could some cancer patients safely treat blood clots at home? New research suggests yes
A predetermined companion report from the ONCO PE trial evaluated 3-month outcomes for home vs.
Active cancer patients with low-risk lung clots can safely take blood thinners at home, avoiding disruptive hospital stays while staying on …
Axitinib + Octreotide Shows PFS Benefit in Extrapancreatic NETs per Central Review (HR 0.71)
Can a blood vessel blocker help slow rare gut tumors? Study shows mixed results for new combination treatment
In the AXINET phase II/III trial, axitinib plus octreotide LAR significantly improved median PFS per blinded independent central review (16.…
A new blood vessel blocker combined with standard hormone shots helped rare gut tumors shrink and delayed growth longer than placebo, despit…